Havemeyer Place LP Acquires New Position in uniQure N.V. $QURE

Havemeyer Place LP purchased a new position in shares of uniQure N.V. (NASDAQ:QURE) in the fourth quarter, Holdings Channel reports. The fund purchased 29,655 shares of the biotechnology company’s stock, valued at approximately $710,000.

Other institutional investors also recently bought and sold shares of the company. Jones Financial Companies Lllp raised its position in uniQure by 509.0% during the 3rd quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock worth $33,000 after buying an additional 509 shares during the last quarter. CIBC Private Wealth Group LLC purchased a new position in uniQure during the 3rd quarter worth approximately $50,000. Torren Management LLC purchased a new position in uniQure during the 4th quarter worth approximately $28,000. FNY Investment Advisers LLC raised its position in uniQure by 76.7% during the 3rd quarter. FNY Investment Advisers LLC now owns 1,654 shares of the biotechnology company’s stock worth $96,000 after buying an additional 718 shares during the last quarter. Finally, IFP Advisors Inc purchased a new position in uniQure during the 4th quarter worth approximately $48,000. 78.83% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at uniQure

In other news, insider Walid Abi-Saab sold 45,000 shares of uniQure stock in a transaction that occurred on Friday, May 8th. The shares were sold at an average price of $25.06, for a total transaction of $1,127,700.00. Following the completion of the transaction, the insider directly owned 169,669 shares of the company’s stock, valued at $4,251,905.14. The trade was a 20.96% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jack Kaye sold 2,645 shares of uniQure stock in a transaction that occurred on Wednesday, June 3rd. The shares were sold at an average price of $30.01, for a total transaction of $79,376.45. Following the transaction, the director directly owned 20,439 shares of the company’s stock, valued at approximately $613,374.39. This trade represents a 11.46% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 4.65% of the stock is owned by insiders.

Analyst Ratings Changes

QURE has been the subject of a number of recent research reports. Wall Street Zen raised shares of uniQure from a “sell” rating to a “hold” rating in a research report on Saturday, March 28th. Mizuho upgraded uniQure from a “neutral” rating to an “outperform” rating and upped their target price for the stock from $12.00 to $35.00 in a research note on Wednesday, March 11th. Wolfe Research assumed coverage on uniQure in a research note on Monday, February 23rd. They issued a “peer perform” rating on the stock. Cantor Fitzgerald restated a “neutral” rating and issued a $9.00 target price (down from $55.00) on shares of uniQure in a research note on Monday, March 2nd. Finally, Barclays decreased their price target on uniQure from $31.00 to $25.00 and set an “equal weight” rating for the company in a report on Monday, March 23rd. Ten investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $42.83.

uniQure Price Performance

NASDAQ:QURE opened at $27.00 on Tuesday. The company has a debt-to-equity ratio of 0.33, a current ratio of 10.40 and a quick ratio of 10.40. The firm has a market cap of $1.70 billion, a price-to-earnings ratio of -7.76 and a beta of 0.98. The company has a 50 day moving average price of $21.62 and a 200-day moving average price of $21.78. uniQure N.V. has a 1-year low of $8.73 and a 1-year high of $71.50.

uniQure (NASDAQ:QURE) last posted its earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share for the quarter, beating the consensus estimate of ($0.88) by $0.03. The firm had revenue of $3.56 million during the quarter, compared to analyst estimates of $5.21 million. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. Equities research analysts forecast that uniQure N.V. will post -3.64 EPS for the current year.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.